2024-516832-82-00
Recruiting
Phase 1/2
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]
Universitaetsklinikum Heidelberg AöR1 site in 1 country63 target enrollmentSeptember 19, 2024
Overview
- Phase
- Phase 1/2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Universitaetsklinikum Heidelberg AöR
- Enrollment
- 63
- Locations
- 1
- Primary Endpoint
- Assessment of toxicities according to the CTCAEv5.0
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The main purpose of the study is to evaluate the safety and feasibility of escalating doses of autologous activated peripheral blood T lymphocytes (ATLs) genetically modified to express third-generation CARs (comprising the CD28 and CD137 (4-1BB) costimulatory domain) that target the CD19 molecule in patients with refractory or relapsed CD19+ lymphoid disease such as ALL or NHL including CLL, DLBCL, FL and/or MCL.
Investigators
Prof. Dr. Michael Schmitt
Scientific
Universitaetsklinikum Heidelberg AöR
Eligibility Criteria
Inclusion Criteria
- •Stratum 1-2 (Adults): Confirmed CD19+ ALL, CLL, DLBCL, FL or MCL in patients ≥ 18 years
- •Stratum 3: Renal function defined as serum creatinine-clearance ≥ 30 mL/min/1.73 m²
- •Stratum 3: Absolute lymphocyte count (ALC) ≥ 100/mm³
- •Stratum 1-2 (Adults): Relapsed or refractory disease (including “molecular relapse” with minimal residual disease (MRD)
- •Stratum 1-2 (Adults): Renal function defined as: serum creatinine of ≤ 2 x ULN or eGFR ≥ 30 mL/min/1.73 m²
- •Stratum 1-2 (Adults): Absolute lymphocyte count (ALC) ≥ 100/mm³
- •Stratum 3: Age of > 3 years until < 18 years at the time of screening
- •Stratum 3: CD19+ ALL (Ph+ and Ph-) confirmed by cytology and flow cytometry (FACS) AND Relapsed or refractory disease
- •Stratum 3: Measurable disease/MRD at time of enrollment
- •Stratum 3: Life expectancy ≥ 12 weeks
Exclusion Criteria
- •Stratum 1-2 (Adults): Immunosuppressive medication with the exception of ≤ 30 mg prednisolone/d or equivalent at the time of CAR TC transfusion
- •Stratum 3: Uncontrolled acute life-threatening bacterial, viral or fungal infection
- •Stratum 1-2 (Adults): Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CD19.CAR TC transfusion
- •Stratum 1-2 (Adults): Florid/acute or chronic Graft-versus-Host disease (GvHD)
- •Stratum 1-2 (Adults): Uncontrolled acute life-threatening bacterial, viral or fungal infection
- •Stratum 1-2 (Adults): A primary malignancy which is in complete remission for ≥ 5 years
- •Stratum 1-2 (Adults): Pregnant or nursing (lactating) women
- •Stratum 3: immunosuppressive medication with the exception of < 0.5 mg/d*kg BW prednisolone-equivalent at the time of CD19.CAR TC transfusion
- •Stratum 3: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CD19.CAR TC transfusion
- •Stratum 3: Florid/acute or chronic Graft-versus-Host disease (GvHD)
Outcomes
Primary Outcomes
Assessment of toxicities according to the CTCAEv5.0
Assessment of toxicities according to the CTCAEv5.0
Assessment of frequency and grade of CRS and/or ICANS
Assessment of frequency and grade of CRS and/or ICANS
Assessment of dose-limiting toxicity (DLT) and maximum tolerated dose (MTD)
Assessment of dose-limiting toxicity (DLT) and maximum tolerated dose (MTD)
Yield of sufficient NCs by leukapheresis
Yield of sufficient NCs by leukapheresis
Successful transduction (>15%) of CD3+ TCs
Successful transduction (>15%) of CD3+ TCs
Yield of the respective dose of transduced TCs (1 to 20x106 transduced CD3+TCs/m2) in the first three dose levels (I-III)
Yield of the respective dose of transduced TCs (1 to 20x106 transduced CD3+TCs/m2) in the first three dose levels (I-III)
Yield of the respective dose of transduced TCs (5 to 20x107 transduced CD3+ TCs/m2) in the second three dose levels (IV-VI)
Yield of the respective dose of transduced TCs (5 to 20x107 transduced CD3+ TCs/m2) in the second three dose levels (IV-VI)
Secondary Outcomes
- Characterization of in vivo cellular pharmakokinetics
- Correlation of clinical response and number of circulating gene modified cells
- Reduction of disease burden with CD19.CAR TC transfusions
- Evaluation of survival and function of chimeric antigen receptor (CAR) TCs directed against CD19 (CD19.CAR TC) in vivo
- Anti-tumor efficacy of CD19.CAR TCs in patients with CD19+ lymphoid disease (overall response rate (ORR), complete response (CR), partial response (PR)) at day 90 (EOS) after CD19.CAR TC transfusion)
- Time to response (at least PR) after the CD19.CAR TC transfusion
- Duration of overall response (DOR) after the CD19.CAR TC transfusion
- Progression-free survival (PFS) after the CD19.CAR TC transfusion
- Overall survival (OS) after the CD19.CAR TC transfusion
- Correlation of B-cell depletion in vivo and response to CD19.CAR TC treatment
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Methotrexate plus Prednisone in patients with relapsingIdiopathic Retroperitoneal Fibrosis.Relapsing Idiopathic Retroperitoneal FibrosisInflammatory and Immune System - Other inflammatory or immune system disordersRenal and Urogenital - Other renal and urogenital disordersRenal and Urogenital - Kidney diseaseACTRN12612000845831Augusto Vaglio15
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 19.1 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-ESovartis Farmacéutica, S.A.55
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000012975MedDRA version: 20.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000012975Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-FRovartis Pharma AG55
Completed
Not Applicable
Clinical study of acupotome treatment of refractory non-specific low back pain based on the theory of regulation and balanceITMCTR2024000200onghua Hospital, Shanghai University of Traditional Chinese Medicine
Not yet recruiting
Not Applicable
Should a patient with a clinically suspected scaphoid fracture be treated with a cast?clinical suspected scaphoid fracture. Klinische verdenking scaphoid fractuurNL-OMON20183Erasmus MC180